\nZura Bio Limited (Nasdaq: \u201cZURA\u201d) (\u201cZura Bio\u201d or the \u201cCompany\u201d), a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders, today announced it will be added to the Russell 2000\u00ae and Russell 3000\u00ae Indexes at the conclusion of the 2023 Russell indexes annual reconstitution, effective after the US market opens on June 26, 2023.\n<\/p>\n
\nAnnual Russell indexes reconstitution captures the 4,000 largest US stocks as of April 28, 2023 ranking them by total market capitalization. Membership in the US all-cap Russell 3000\u00ae Index, which remains in place for one year, means automatic inclusion in the small-cap Russell 2000\u00ae Index as well as the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes.\n<\/p>\n
\n\u201cWe believe that Zura Bio\u2019s inclusion in the Russell 2000\u00ae and 3000\u00ae indexes reflects the market\u2019s appreciation of our clinical pipeline, our recently completed financing, and the potential of Zura Bio as a leader in controlling immune mediated diseases,\u201d said Verender Badial, Chief Financial Officer of Zura Bio. \u201cWe expect that joining the index will further raise awareness of Zura Bio among the investment community and we look forward to a potentially increased weighting in the indexes following the next quarterly rebalance that will take into account our recently closed financing.\u201d\n<\/p>\n
\nThe inclusion in the indexes was based on the market capitalization of Zura Bio on April 28, 2023. The next quarterly index rebalance in September will consider the increased capitalization and public float from the new shares issued in a private placement transaction which closed in two tranches, the first in May 2023 and the second in June 2023. A registration statement on Form S-1 covering the resale of such newly issued shares has been filed with the Securities and Exchange Commission.\n<\/p>\n
\nRussell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Approximately $12.1 trillion in assets are benchmarked against Russell\u2019s US indexes. Russell indexes are part of FTSE Russell, a leading global index provider.\n<\/p>\n
About Zura Bio<\/b><\/p>\n
\nZura Bio is a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders. Currently, Zura Bio is developing three assets which have completed phase 1\/1b studies and are Phase 2 ready. The company is developing a portfolio of therapeutic indications for tibulizumab (ZB-106), torudokimab (ZB-880), and ZB-168 with a goal of demonstrating their efficacy, safety, and dosing convenience in immune and inflammatory disorders.\n<\/p>\n
About FTSE Russell<\/b><\/p>\n
\nFTSE Russell is a global index leader that provides innovative benchmarking, analytics and data solutions for investors worldwide. FTSE Russell calculates thousands of indexes that measure and benchmark markets and asset classes in more than 70 countries, covering 98% of the investable market globally.\n<\/p>\n
\nFTSE Russell index expertise and products are used extensively by institutional and retail investors globally. Approximately $20.1 trillion is currently benchmarked to FTSE Russell indexes. For over 30 years, leading asset owners, asset managers, ETF providers and investment banks have chosen FTSE Russell indexes to benchmark their investment performance and create ETFs, structured products and index-based derivatives.\n<\/p>\n
\nA core set of universal principles guides FTSE Russell index design and management: a transparent rules-based methodology is informed by independent committees of leading market participants. FTSE Russell is focused on applying the highest industry standards in index design and governance and embraces the IOSCO Principles. FTSE Russell is also focused on index innovation and customer partnerships as it seeks to enhance the breadth, depth and reach of its offering.\n<\/p>\n
\nFTSE Russell is wholly owned by London Stock Exchange Group.\n<\/p>\n
\nFor more information, visit www.ftserussell.com<\/a>.\n<\/p>\n Forward Looking Statements Disclaimer<\/b><\/p>\n \nThis communication includes \u201cforward-looking statements\u201d within the meaning of the \u201csafe harbor\u201d provisions of the Private Securities Litigation Reform Act of 1995. Words such as \u201cexpect,\u201d \u201cestimate,\u201d \u201cproject,\u201d \u201cbudget,\u201d \u201cforecast,\u201d \u201canticipate,\u201d \u201cintend,\u201d \u201cplan,\u201d \u201cmay,\u201d \u201cwill,\u201d \u201ccould,\u201d \u201cshould,\u201d \u201cbelieve,\u201d \u201cpredict,\u201d \u201cpotential,\u201d \u201ccontinue,\u201d \u201cstrategy,\u201d \u201cfuture,\u201d \u201copportunity,\u201d \u201cwould,\u201d \u201cseem,\u201d \u201cseek,\u201d \u201coutlook\u201d and similar expressions are intended to identify such forward-looking statements. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties that could cause the actual results to differ materially from the expected results. These statements are based on various assumptions, whether or not identified in this communication. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability.\n<\/p>\n \nActual events and circumstances are difficult or impossible to predict and will differ from assumptions. You should carefully consider the risks and uncertainties described in the \u201cRisk Factors\u201d sections of Zura Bio\u2019s recent filings with the SEC. These filings would identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Many of these factors are outside Zura Bio\u2019s control and are difficult to predict. Many factors could cause actual future events to differ from the forward-looking statements in this communication, including but not limited to: (1) the outcome of any legal proceedings that may be instituted against Zura Bio; (2) volatility in the price of Zura Bio\u2019s securities; (3) the ability of Zura Bio to successfully conduct research and development activities, grow and manage growth profitably, maintain relationships with customers and suppliers, and retain key employees; (4) the ongoing costs relating to operating as a public company; (5) changes in the applicable laws or regulations; (6) the possibility that Zura Bio may be adversely affected by other economic, business, and\/or competitive factors; (7) the risk of downturns and a changing regulatory landscape in the highly competitive industry in which Zura Bio operates; (8) the potential inability of Zura Bio to raise additional capital needed to pursue its business objectives or to achieve efficiencies regarding other costs; (9) the enforceability of Zura Bio\u2019s intellectual property, including its patents, and the potential infringement on the intellectual property rights of others, cyber security risks or potential breaches of data security; and (10) other risks and uncertainties described in the registration statement on Form S-1 filed with the SEC on June 14, 2023, and such other documents filed by Zura Bio from time to time with the SEC. These risks and uncertainties may be amplified by the COVID-19 pandemic or other unanticipated global disruption events, which may continue to cause economic uncertainty. Zura Bio cautions that the foregoing list of factors is not exclusive or exhaustive and not to place undue reliance upon any forward-looking statements, including projections, which speak only as of the date made. Zura Bio gives no assurance that it will achieve its expectations.\n<\/p>\n \nZura Bio does not undertake or accept any obligation to publicly provide revisions or updates to any forward-looking statements, whether as a result of new information, future developments or otherwise, or should circumstances change, except as otherwise required by securities and other applicable laws.\n<\/p>\n View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20230623307391\/en\/<\/a><\/span><\/p>\n Investors: KEYWORDS:<\/b> California United States North America<\/p>\n INDUSTRY KEYWORDS:<\/b> Biotechnology Pharmaceutical Health Clinical Trials<\/p>\n<\/p>\n
\n<\/b>
Zura Bio
\n
Megan Weinshank
\n
info@zurabio.com<\/a><\/p>\n
![\"Logo\"](\"https:\/\/mms.businesswire.com\/media\/20230623307391\/en\/1763843\/3\/Zura_Bio_Logo.jpg\"){kind=logo}
<\/td>\n<\/tr>\n